| Anemic (n = 216) | Not Anemic (n = 122) | p-value |
---|---|---|---|
Age* | 68 ± 10 years | 64 ± 10 years | 0.001 |
Gender | 37 (17%) Female | 35 (29%) Female | 0.018 |
179 (83%) Male | 87 (71%) Male | ||
Anemic at Diagnosis** 120/289 (42%) | 113 (62%) | 7 (7%) | 0.0002 |
Clinical T Stage (N = 289) | 1 13(7%) 2 17 (9%) 3 157 (83%) 4 2 (1%) | 1 25 (25%) 2 20 (20%) 3 55 (55%) 4 0 (0%) | < 0.0001 |
Tumor Histology | 33 (16%) Squamous 178 (84%) Adenoca | 15 (12%) Squamous 106 (88%) Adenoca | 0.52 |
Treated with NARx | 166 (77%) | 47 (39%) | < 0.0001 |
Diagnosis to OR (days)*,$ | 148 ± 539 days | 130 ± 39 days | 0.01 |
Complete Response (CR) to NARx$ | 57 (34%) | 19 (40%) | 0.49 |
Estimated Blood Loss (EBL)* | 280 ± 180 ml | 289 ± 215 ml | 0.72 |
Pathologic/Surgical T Stage | 0 59 (27%) 1 36 (17%) 2 42 (20%) 0 75 (36%) 1 2 (1%) In-Situ 1 (< 1%) | 0 21 (17%) 1 46 (38%) 2 18 (15%) 0 34 (28%) 1 0 (0%) In-Situ 3 (2%) | 0.0002 |
Lymph Node Status | 138 (64%) Negative | 78 (64%) Negative | 1.00 |
77 (36%) Positive | 44 (36%) Positive | ||
Hospital Length of Stay * | 11 ± 11 days | 11 ± 11 days | 0.66 |